Yahoo
NasdaqGM - Delayed Quote USD

Anbio Biotechnology (NNNN)

3.6800 +0.0950 (+2.65%)
At close: 4:00:00 PM EST
Trade NNNN on Coinbase
Chart Range Bar
Loading chart for NNNN
  • Previous Close 3.5850
  • Open 3.5500
  • Bid 11.5500 x 100
  • Ask 9.8900 x 100
  • Day's Range 3.5500 - 3.7900
  • 52 Week Range 3.0900 - 44.7300
  • Volume 22,851
  • Avg. Volume 149,965
  • Market Cap (intraday) 161.52M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 24.53
  • EPS (TTM) 0.1500
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

www.anbiobiotechnology.com

27

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NNNN
87.76%
S&P 500 (^GSPC)
12.32%

1-Year Return

NNNN
73.66%
S&P 500 (^GSPC)
13.54%

3-Year Return

NNNN
30.04%
S&P 500 (^GSPC)
76.41%

5-Year Return

NNNN
30.04%
S&P 500 (^GSPC)
64.28%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    74.05%

  • Return on Assets (ttm)

    14.66%

  • Return on Equity (ttm)

    27.05%

  • Revenue (ttm)

    8.65M

  • Net Income Avi to Common (ttm)

    6.4M

  • Diluted EPS (ttm)

    0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.9M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.61M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: